UK cost-effectiveness agency NICE has published guidance on the use of COVID-19 therapies that can be used for at-risk patients, focusing on three drugs that can be used o
Pfizer reaped the rewards of its COVID-19 vaccines and therapeutics in 2022, but there are already signs of falling demand that looks likely to get significantly worse in
NICE has recommended that three COVID-19 therapies can continue to be used to treat patients – Pfizer's Paxlovid, Roche's RoActemra, and Eli Lilly's Olumiant – but turned down another five
US startup Dr B – formed in 2021 to help match patients seeking a COVID-19 vaccine to suppliers with leftover stock – is branching out into antivirals with the help of an $8 million fundrai
Some patients with COVID-19 will be able to get easier access to Pfizer's oral antiviral therapy Paxlovid, after the FDA ruled that pharmacists would be able to prescribe the drug.
US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid infringes one of its patents and seeking damages from the pharma giant.
Japanese pharma group Eisai says it is battling a ransomware attack that was launched last weekend and has resulted in some of its servers becoming encrypted.
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas